LUMiC® endoprosthesis for pelvic reconstruction: A Canadian experience Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • AbstractBackground and ObjectivesThe LUMiC® prosthesis was introduced to reduce the mechanical complications encountered with periacetabular reconstruction after pelvic tumor resection. Few have evaluated the outcomes associated with its use.MethodsA retrospective study from five Orthopedic Oncology Canadian centers was conducted. All patients with a LUMiC® endoprosthesis were included. Their charts were reviewed for surgical and functional outcomes.ResultsA total of 16 patients were followed for 28 months (3–60). A total of 12 patients (75%) had a LUMiC® after a resection of a primary sarcoma. Mean surgical time was 555 min. Four patients (25%) had a two‐stages procedure. MSTS score was 60.3 preoperatively and 54.3 postoperatively. Patients got a dual mobility bearing and the silver coated implant was used in 7 patients (43.7%). Five patients (31.3%) underwent capsular reconstruction using a fabric. Silver‐coating was not found to reduce infection risk (p = 0.61) and capsuloplasty did not prevent dislocation (p = 0.6). Five patients had peroperative complications (31.3%). Eight patients (50%) had an infection including all four with two‐stages surgery. Dislocation occurred in five patients (31.3%) whereas no cases of aseptic loosening were reported. A total of 10 patients (62.5%) needed a reoperation.ConclusionLUMiC® endoprosthesis provides low rates of aseptic loosening on medium‐term follow‐up. Infection and dislocation are common complications but we were unable to show benefits of capsuloplasty and silver‐coated implants.


  • Rizkallah, Maroun
  • Ferguson, Peter C
  • Basile, Georges
  • Kim, Paul
  • Werier, Joel
  • Wilson, David
  • Turcotte, Robert

publication date

  • March 2023